"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 7604811 B1,160-004-843-909-213,2009-10-20,2009,US 76275796 A,1996-12-10,US 76275796 A;;US 39698695 A;;US 52194590 A;;US 59030884 A;;US 19137494 A;;US 69048591 A,1984-03-16,Oral-intestinal vaccines against diseases caused by enteropathic organisms using antigens encapsulated within biodegradable-biocompatible microspheres,This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.,US ARMY,JARBOE DANIEL L;;REID ROBERT H;;BOEDEKER EDGAR C;;CASSELS FREDERICK J,UNITED STATES ARMY (2001-11-17),https://lens.org/160-004-843-909-213,Granted Patent,yes,48,0,4,53,39,A61K9/1647;;A61K38/00;;A61K39/39;;A61K2039/55555;;C07K14/245;;A61P37/04;;Y02A50/30;;C07K14/245;;A61K9/1647;;A61K39/39;;A61K2039/55555;;A61K38/00;;Y02A50/30,A61K9/00;;A61K9/16;;A61K38/00;;A61K38/04;;A61K39/39;;C07K5/00;;C07K7/00;;C07K14/245,424/257.1;;530/328,27,22,004-083-932-038-706;;161-357-459-129-888;;039-426-486-767-563;;076-766-447-891-134;;071-812-555-686-501;;034-987-431-948-226;;003-017-479-555-526;;076-766-447-891-134;;039-426-486-767-563;;071-812-555-686-501;;033-109-667-155-067;;041-699-756-014-816;;024-808-525-931-215;;020-187-927-955-856;;111-491-328-638-803;;022-996-702-056-422;;056-647-556-613-881;;084-925-232-325-122;;161-357-459-129-888;;030-191-653-720-201;;050-149-514-307-35X;;138-561-636-084-567,8519480;;10.1007/bf01569828;;pmc257140;;1375193;;10.1128/iai.60.6.2174-2181.1992;;10.1128/iai.25.2.738-748.1979;;39896;;pmc414505;;pmc210515;;10.1128/jb.171.11.6372-6374.1989;;2572583;;pmc313240;;10.1128/iai.57.4.1126-1130.1989;;2564374;;8094929;;10.1016/0264-410x(93)90012-m;;10.1016/0032-3861(79)90009-0;;pmc210515;;10.1128/jb.171.11.6372-6374.1989;;2572583;;10.1128/iai.25.2.738-748.1979;;39896;;pmc414505;;pmc313240;;10.1128/iai.57.4.1126-1130.1989;;2564374;;10.1016/0168-3659(94)00123-c;;10.1016/0168-3659(94)90233-x;;10.1016/0168-3659(91)90127-y;;1977705;;pmc313703;;10.1128/iai.58.11.3594-3600.1990;;10.1016/0378-1097(91)90607-c;;10.1016/s0021-9258(19)39033-7;;1692321;;10.1016/0378-1097(89)90179-1;;10.1111/j.1574-6968.1989.tb03561.x;;2465904;;10.1002/eji.1830190108;;pmc257140;;1375193;;10.1128/iai.60.6.2174-2181.1992;;2151722;;10.3109/08830189009056618;;1594579;;10.1002/prot.340130107;;10.1038/332845a0;;3258651,"Cassels, F.J., et al. J. Ind. Microbiol. 1995;15:214-226.;;Cassels, F.J., et al. Infec. Immun. Jun. 1992;60(6):2174-2181.;;Evans, D. G. et al., Infect. lmmun. 25:738-748, ""Purification and characterization of the CFA/I antigen of enterotoxic Esherichia coli"", Aug. 1979.;;Hall, R. H. et al., J. Bacteriol. 171:6372-74, ""Purification and analysis of colonization factor antigen I, coli surace antigen I and coli surfac antigen 3 fimbriae from enterotoxigenic Escherichia coli"", Nov. 1989.;;Karjalainen, T. K. et al., Infect. Immun. 57:1126-1130, ""Molecular cloning of nucleotide sequence of the colonization factor antigen I gene of Escherichia coli"", Apr. 1989.;;Edelman, et al., Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide), Vaccine, vol. 11, Issue 2, p. 155-158, (1993).;;Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp. 1459-1464.;;Biotechnology News, Aug. 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.;;Hall, et al., Purification and Analysis of Colonization Factor Antigen I, Coli Surface Antigen 1, and Coli Surface ANtigen 3 Fimbriae from Enterotoxigenic Escherichia coli, Journal of Bacteriology, Nov. 1989, p. 6372-6374, vol. 171, No. 11.;;Evans, et al. Purification and Characterization of the CFR/I Antigen of Enterotoxigenic Escherichia coli, Infection and Immunity, Aug. 1979, p. 738-748, vol. 25.;;Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene of Escherichia coli, Infection and Immunity, Apr. 1989, p. 1126-1130, vol. 57.;;Jeyanthi, et al., Novel, Burst Free Programmable Biodegradable Microspheres for Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p. 351-352/.;;Yeh, A novel emulsification-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1005) 437-445.;;Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by watewr-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.;;Wang, et al., Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.;;Brown, Wonder Drugs' Losing Healing Aura, The Washing Post, Jun. 26, 1995, A section.;;Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound Infection Control, Chemical Abstracts, 1983, pp. 215-226.;;Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pill of Human Enterotoxigenic Escherichia coli, Infection and Immunity, Nov. 1990, p. 3594-3600, vol. 58, No. 11.;;Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human enterotoxigenic Escherichia coli of serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p. 265-270.;;Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by Systematic Synthesis of Peptides on solid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990).;;McConnel, et al., Antigenic homology within human enterotoxigenic Esherichia coli fimbrial colonization factor antigens: CFA/I, coli-surface-associated antigens (CS)1, CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.;;Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.;;Cassels, et al., Analysis of Escherichia coli Colonization Factor Antigen I Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, Jun. 1992, p. 2174-2181, vol. 60, No. 6.;;Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 00 61-73.;;Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, Apr. 19, 1994, p. 4.;;Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).;;Brown, A hypothetical model of the foreign antigen biinding site of Class II histocompatibility molecules, Nature, vol. 332, Apr. 28, 1988, p. 845-850.",EXPIRED
2,US,A1,US 2010/0074913 A1,072-315-679-989-407,2010-03-25,2010,US 58496709 A,2009-09-15,US 58496709 A;;US 76275796 A;;US 39698695 A;;US 19137494 A;;US 69048591 A;;US 52194590 A;;US 59030884 A,1984-03-16,Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres,This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.,BOEDEKER EDGAR C;;CASSELS FREDERICK J;;JARBOE DANIEL L;;REID ROBERT H,BOEDEKER EDGAR C;;CASSELS FREDERICK J;;JARBOE DANIEL L;;REID ROBERT H,,https://lens.org/072-315-679-989-407,Patent Application,yes,0,0,4,53,39,A61K9/1647;;A61K38/00;;A61K39/39;;A61K2039/55555;;C07K14/245;;A61P37/04;;Y02A50/30;;C07K14/245;;A61K9/1647;;A61K39/39;;A61K2039/55555;;A61K38/00;;Y02A50/30,A61K39/00;;A61K9/00;;A61K9/16;;A61K38/00;;A61K39/39;;A61P37/04;;C07K14/245,424/185.1,0,0,,,,DISCONTINUED
3,AU,A,AU 1991/083036 A,103-116-842-610-796,1992-12-21,1992,AU 1991/083036 A,1991-05-13,US 69048591 A,1991-04-24,ORAL-INTESTINAL VACCINES AGAINST DISEASES CAUSED BY ENTEROPATHOGENIC ORGANISMS USING ANTIGENS ENCAPSULATED WITHIN BIODEGRADABLE-BIOCOMPATIBLE MICROSPHERES,,UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY,ROBERT H REID;;DANIEL JARBOE;;FREDERICK J CASSELS;;EDGAR C BOEDEKER;;JEAN A SETTERSTROM,,https://lens.org/103-116-842-610-796,Patent Application,no,0,0,4,53,0,A61K9/1647;;A61K38/00;;A61K39/39;;A61K2039/55555;;C07K14/245;;A61P37/04;;Y02A50/30;;C07K14/245;;A61K9/1647;;A61K39/39;;A61K2039/55555;;A61K38/00;;Y02A50/30,A61K9/00;;A61K9/16;;A61K38/00;;A61K39/39;;C07K14/245,,0,0,,,,PENDING
4,WO,A1,WO 1992/019263 A1,136-264-968-812-184,1992-11-12,1992,US 9103328 W,1991-05-13,US 69048591 A,1991-04-24,ORAL-INTESTINAL VACCINES AGAINST DISEASES CAUSED BY ENTEROPATHOGENIC ORGANISMS USING ANTIGENS ENCAPSULATED WITHIN BIODEGRADABLE-BIOCOMPATIBLE MICROSPHERES,This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.,US ARMY,REID ROBERT H;;JARBOE DANIEL;;CASSELS FREDERICK J;;BOEDEKER EDGAR C;;SETTERSTROM JEAN A,,https://lens.org/136-264-968-812-184,Patent Application,yes,2,12,4,53,0,A61K9/1647;;A61K38/00;;A61K39/39;;A61K2039/55555;;C07K14/245;;A61P37/04;;Y02A50/30;;C07K14/245;;A61K9/1647;;A61K39/39;;A61K2039/55555;;A61K38/00;;Y02A50/30,A61K9/00;;A61K9/16;;A61K38/00;;A61K39/39;;C07K14/245,,5,5,056-647-556-613-881;;084-925-232-325-122;;040-175-292-706-908;;071-812-555-686-501;;012-830-491-824-205,10.1016/0378-1097(89)90179-1;;10.1111/j.1574-6968.1989.tb03561.x;;2465904;;10.1002/eji.1830190108;;6682834;;10.1128/iai.40.3.888-893.1983;;pmc348135;;pmc313240;;10.1128/iai.57.4.1126-1130.1989;;2564374;;pmc345355;;6204335;;10.1073/pnas.81.13.3998,"FEMS MICROBIOLOGY LETTERS, Volume 61, issued 1989, MCCONNEL et al., ""Antigenic Homology within Human Enteroxigenic Escherichia Coli Fimbrial Colonization Factor Antigens: CFA/I, Coli-Surface-Associated Antigens (CS) 1, C52, C54 and CS17"", pages 105-108.;;EUROPEAN J. IMMUNOL, Volume 19, issued 1989, VAN DE ZEE et al., ""Efficient Mapping and Characterization of a T-Cell Epitope by the Simultaneous Synthesis of Multiple Peptides"", pages 43-47.;;INFECTION AND IMMUNITY, Volume 40, No. 3, issued June 1983, KLIPSTEIN et al., ""Protection of Rabbits Immunized with a Vaccine of Escherchia Coli Heat Stable Toxin Cross-Linked to Heat Labile Toxin B. Sunbunit"", pages 888-893.;;INFECTION AND IMMUNITY, Volume 57, No. 4, issued April 1989, KARJALAINEN et al., ""Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene of Escherichia Coli"", pages 1126-1130.;;PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 81, issued July 1984, GEYSER et al., ""Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to Resolution of a Single Amino Acid"", pages 3998-4002.",PENDING
5,US,A1,US 2006/0004260 A1,175-429-612-006-066,2006-01-05,2006,US 17405205 A,2005-07-01,US 17405205 A;;US 6860005 A;;US 28519002 A;;US 41854299 A,1999-10-14,Endotracheal video device,An endotracheal device for use with a supra-laryngeal mask including a video display for providing images of the area ahead of the endotracheal device to facilitate insertion without damaging the surrounding tissue; the endotracheal device having a flexible portion and a rigid portion maintaining a light and an image guide for transmitting illuminating light ahead of the endotracheal device and for transmitting reflected light from the area ahead of the endotracheal device.,BOEDEKER BEN;;BERCI GEORGE;;KAPLAN MARSHAL B;;BARRY JAMES P;;CHATENEVER DAVID;;IRION KLAUS M;;EHRHARDT ANDRE;;RUDISCHHAUSER JURGEN;;MATTSSON-BOZE DANIEL,BOEDEKER BEN;;BERCI GEORGE;;KAPLAN MARSHAL B;;BARRY JAMES P;;CHATENEVER DAVID;;IRION KLAUS M;;EHRHARDT ANDRE;;RUDISCHHAUSER JURGEN;;MATTSSON-BOZE DANIEL,KARL STORZ GMBH & CO. KG; A GERMAN LIMITED PARTNERSHIP (2005-07-09);;BOARD REGENTS OF THE UNIVERSITY OF NEBRASKA (2009-05-01),https://lens.org/175-429-612-006-066,Patent Application,yes,35,69,4,4,0,A61B1/00165;;A61B1/042;;A61B1/267;;A61M16/04;;A61M16/0488;;A61B1/07;;A61M16/0409;;A61M16/0488;;A61B1/042;;A61B1/267;;A61B1/00165;;A61M16/04;;A61B1/07;;A61M16/0409,A61B1/267,600/188;;600/199,0,0,,,,DISCONTINUED
6,DE,D1,DE 602006021365 D1,183-357-339-035-447,2011-06-01,2011,DE 602006021365 T,2006-07-03,US 17405205 A,2005-07-01,Endotracheale Videovorrichtung,,STORZ KARL GMBH & CO KG,BOEDEKER BEN;;BERCI GEORGE;;KAPLAN MARSHAL B;;BARRY JAMES P;;CHATENEVER DAVID;;IRION KLAUS M DR-ING;;EHRHARDT ANDRE;;RUDISCHHAUSER JUERGEN;;MATTSSON-BOZE DANIEL,,https://lens.org/183-357-339-035-447,Granted Patent,no,0,0,4,4,0,A61B1/00165;;A61B1/042;;A61B1/267;;A61M16/04;;A61M16/0488;;A61B1/07;;A61M16/0409;;A61M16/0488;;A61B1/042;;A61B1/267;;A61B1/00165;;A61M16/04;;A61B1/07;;A61M16/0409,A61M16/04;;A61B1/267,,0,0,,,,ACTIVE
7,EP,B1,EP 1738789 B1,152-240-420-088-083,2011-04-20,2011,EP 06013710 A,2006-07-03,US 17405205 A,2005-07-01,Endotracheal video device,,STORZ KARL GMBH & CO KG,BOEDEKER BEN;;BERCI GEORGE;;KAPLAN MARSHAL B;;BARRY JAMES P;;CHATENEVER DAVID;;IRION KLAUS M DR-ING;;EHRHARDT ANDRE;;RUDISCHHAUSER JUERGEN;;MATTSSON-BOZE DANIEL,,https://lens.org/152-240-420-088-083,Granted Patent,yes,9,1,4,4,0,A61B1/00165;;A61B1/042;;A61B1/267;;A61M16/04;;A61M16/0488;;A61B1/07;;A61M16/0409;;A61M16/0488;;A61B1/042;;A61B1/267;;A61B1/00165;;A61M16/04;;A61B1/07;;A61M16/0409,A61M16/04;;A61B1/267,,0,0,,,,ACTIVE
8,EP,A1,EP 1738789 A1,002-962-146-850-148,2007-01-03,2007,EP 06013710 A,2006-07-03,US 17405205 A,2005-07-01,Endotracheal video device,"An endotracheal device (14) for use with a supra-laryngeal mask (200) including a video display (274) for providing images of the area ahead of the endotracheal device to facilitate insertion without damaging the surrounding tissue; the endotracheal device having a flexible portion (256) and a rigid portion (258) maintaining a light and an image guide for transmitting illuminating light ahead of the endotracheal device and for transmitting reflected light from the area ahead of the endotracheal device.
",STORZ KARL GMBH & CO KG,BOEDEKER BEN;;BERCI GEORGE;;KAPLAN MARSHAL B;;BARRY JAMES P;;CHATENEVER DAVID;;IRION KLAUS M DR-ING;;EHRHARDT ANDRE;;RUDISCHHAUSER JUERGEN;;MATTSSON-BOZE DANIEL,,https://lens.org/002-962-146-850-148,Patent Application,yes,14,2,4,4,0,A61B1/00165;;A61B1/042;;A61B1/267;;A61M16/04;;A61M16/0488;;A61B1/07;;A61M16/0409;;A61M16/0488;;A61B1/042;;A61B1/267;;A61B1/00165;;A61M16/04;;A61B1/07;;A61M16/0409,A61M16/04;;A61B1/267,,0,0,,,,ACTIVE
9,US,B1,US 6309669 B1,058-770-203-889-950,2001-10-30,2001,US 78973497 A,1997-01-27,US 78973497 A;;CN 96194768 A;;US 59097396 A;;US 44614995 A;;US 44614895 A;;US 86730192 A;;US 59030884 A,1984-03-16,Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix,"Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.",US ARMY,SETTERSTROM JEAN A;;VAN HAMONT JOHN E;;REID ROBERT H;;JACOB ELLIOT;;JEYANTHI RAMASUBBU;;BOEDEKER EDGAR C;;MCQUEEN CHARLES E;;JARBOE DANIEL L;;CASSELS FREDERICK;;BROWN WILLIAM;;THIES CURT;;TICE THOMAS R;;ROBERTS F DONALD;;FRIDEN PHIL,ARMY GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE (1997-02-05),https://lens.org/058-770-203-889-950,Granted Patent,yes,14,443,4,53,0,A61K9/1611;;A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/5026;;A61K9/5031;;A61K39/00;;A61K39/0258;;A61K39/292;;A61K38/09;;A61K38/1729;;A61K45/06;;A61K2039/545;;A61K2039/55505;;A61K2039/55555;;C12N2730/10134;;A61K39/12;;Y02A50/30;;A61K39/292;;A61K9/5031;;A61K39/00;;A61K9/1641;;A61K39/0258;;A61K9/1617;;A61K9/5026;;A61K9/1611;;A61K9/1635;;A61K9/1647;;A61K38/09;;A61K38/1729;;A61K45/06;;A61K2039/545;;A61K2039/55555;;A61K2039/55505;;A61K39/12;;C12N2730/10134;;Y02A50/30,A61K9/16;;A61K9/50;;A61K9/52;;A61K38/17;;A61K38/19;;A61K39/00;;A61K39/02;;A61K39/108;;A61K39/29;;F23G5/50;;G05B23/02,424/486;;424/484;;424/422;;424/423;;424/424;;424/425,5,3,024-808-525-931-215;;041-699-756-014-816;;033-109-667-155-067,10.1016/0168-3659(91)90127-y;;10.1016/0168-3659(94)90233-x;;10.1016/0168-3659(94)00123-c,"Materials 1996. Pp. 351-352.;;Wang et al. Influence of Formulation Methods on the in vitro Controlled Release of Protein from Poly(ester) Microspheres. J. of Controlled Release. Sep. 1991, vol. 17, pp. 23-31.*;;Yan et al. Characterization and Morphological Analysis of Protein-Loaded Poly(Lactide-co-Glycolide) Microparticles Prepared by WOW Emulsion Technique. J. of Con. Rel. 1994, 32(3). pp. 231-241.*;;Yeh et al. A Novel Emulsification-Solvent extraction Technique for Production of Protein Loaded Biodegradable Microparticles for vaccine and Drug Delivery. 1995, 33(3), pp. 437-445.*;;Jeyanthi et al. Novel, Burst-Free, Programmable Biodegradable Microspheres for Controlled Release of Polypeptides. In: Proceedings International Symposium on Controlled Release of Bioactive.*",EXPIRED
10,US,B1,US 6844010 B1,123-144-865-210-705,2005-01-18,2005,US 61857700 A,2000-07-18,US 61857700 A;;US 78973497 A;;US 59097396 A;;US 44614995 A;;US 59030884 A;;US 86742697 A;;US 44614895 A,1984-03-16,Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix,"Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group, and end-capped forms ranging in ratios from 100/0 to 1/99.",US ARMY,SETTERSTROM JEAN A;;VAN HAMONT JOHN E;;REID ROBERT H;;JACOB ELLIOT;;JEYANTHI RAMASUBBU;;BOEDEKER EDGAR C;;MCQUEEN CHARLES E;;JARBOE DANIEL L;;CASSELS FREDERICK;;BROWN WILLIAM;;THIES CURT;;TICE THOMAS R;;ROBERTS F DONALD;;FRIDEN PHIL,ARMY UNITED STATES (1997-02-05),https://lens.org/123-144-865-210-705,Granted Patent,yes,49,29,4,53,44,A61K9/1611;;A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K9/1647;;A61K9/5026;;A61K9/5031;;A61K39/00;;A61K39/0258;;A61K39/292;;A61K38/09;;A61K38/1729;;A61K45/06;;A61K2039/545;;A61K2039/55505;;A61K2039/55555;;C12N2730/10134;;A61K39/12;;Y02A50/30;;A61K39/292;;A61K9/5031;;A61K39/00;;A61K9/1641;;A61K39/0258;;A61K9/1617;;A61K9/5026;;A61K9/1611;;A61K9/1635;;A61K9/1647;;A61K38/09;;A61K38/1729;;A61K45/06;;A61K2039/545;;A61K2039/55555;;A61K2039/55505;;A61K39/12;;C12N2730/10134;;Y02A50/30,A61K9/16;;A61K9/50;;A61K9/52;;A61K38/17;;A61K38/19;;A61K39/00;;A61K39/02;;A61K39/108;;A61K39/29;;F23G5/50;;G05B23/02,424/501;;424/501;;424/486;;424/499;;424/422;;424/491;;424/493;;424/426;;514/570;;514/2;;514/12;;530/350;;530/300,21,16,003-017-479-555-526;;076-766-447-891-134;;039-426-486-767-563;;071-812-555-686-501;;033-109-667-155-067;;041-699-756-014-816;;024-808-525-931-215;;020-187-927-955-856;;111-491-328-638-803;;022-996-702-056-422;;056-647-556-613-881;;084-925-232-325-122;;161-357-459-129-888;;030-191-653-720-201;;050-149-514-307-35X;;138-561-636-084-567,10.1016/0032-3861(79)90009-0;;pmc210515;;10.1128/jb.171.11.6372-6374.1989;;2572583;;10.1128/iai.25.2.738-748.1979;;39896;;pmc414505;;pmc313240;;10.1128/iai.57.4.1126-1130.1989;;2564374;;10.1016/0168-3659(94)00123-c;;10.1016/0168-3659(94)90233-x;;10.1016/0168-3659(91)90127-y;;1977705;;pmc313703;;10.1128/iai.58.11.3594-3600.1990;;10.1016/0378-1097(91)90607-c;;10.1016/s0021-9258(19)39033-7;;1692321;;10.1016/0378-1097(89)90179-1;;10.1111/j.1574-6968.1989.tb03561.x;;2465904;;10.1002/eji.1830190108;;pmc257140;;1375193;;10.1128/iai.60.6.2174-2181.1992;;2151722;;10.3109/08830189009056618;;1594579;;10.1002/prot.340130107;;10.1038/332845a0;;3258651,"Gilding, Biodegradable polymers for use in surgery-polyglycolic/poly (ac c acid) homo- and copolymers: 1, Polymer, vol. 20, Dec. 1979, pp1459-1464.;;Biotechnology News, Aug. 22, 1997, vol. 17, No. 20, Topical DNA vaccine elicits immune response.;;Hall, et al., Purification and Analysis of Colonization Factor Antigen I, Coli Surface Antigen 1, and Coli Surface ANtigen 3 Fimbriae from Enterotoxigenic Escherichia coli, Journal of Bacteriology, Nov. 1989, p6372-6374, vol. 171, No. 11.;;Evans, et al. Purification and Characterization of the CFR/I Antigen of Enterotoxigenic Escherichia coli, Infection and Immunity, Aug. 1979, p 738-748, vol. 25.;;Karjalainen, et al., Molecular Cloning and Nucleotide Sequence of the Colonization Factor Antigen I Gene of Escherichia coli, Infection and Immunity, Apr. 1989, p1126-1130, vol. 57.;;Jeyanthi, et al., Novel, Burst Free Programmable Biodegradable Microspheres For Controlled Release of Polypeptides, Proceedings Int. Symp. control Release Bioact. Mater. (1996) p351-352/.;;Yeh, A novel emulsificaton-solvent extraction technique for production of protein loaded biodegradable microparticles for vaccine and drug delivery, Journal of Controlled Release, 33 (1005) 437-445.;;Yan, Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by watewr-in-oil-in-water emulsion technique, Journal of Controlled Release, 32 (1994) 231-241.;;Wang, et al., Influence of formulation methods on the in vitro controlled release of protein from poly (ester) microspheres Journal of Controlled Release, 17 (1991) 23-32.;;Brown, Wonder Drugs' Losing Healing Aura, The Washing Post, Jun. 26, 1995, A section.;;Setterstrom, Controlled Release of Antibiotics From biodegradable Microcapsules For Wound infection Control, Chemical Abstracts, 1983, pp215-226.;;Perez-Casal, et al., Gene Encoding the Major Subunit of CS1 Pili of Human Enterotoxigenic Escherichia coli, Infection and Immunity, Nov., 1990, p 3594-3600, vol. 58, No. 11.;;Jordi, et al., Analysis of the first two genes of the CS1 fimbrial operon in human enterotoxigenic Escherichia coli of serotype 0139: H28, FEMS Microbiology Letters 80, (1991) p265-270.;;Tan, et al., Mapping the Antigenic Epitopes of Human Dihydrofolate Reductase by Systematic Synthesis of Peptides on solid Supports, The Journal of Biological Chemistry, vol. 265, No. 14, Issue of May 15, pp. 8022-8026 (1990).;;McConnel, et al., Antigenic homology within human enterotoxigenic Esherichia coli fimbrial colonization factor antigens: CFA/I, coli-surface-associated antigens (CS)1, CS2, CS4 and CS17, FEMS Microbiology Letters 61 (1989) 105-108.;;Van der Zee, Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol. 1989, 19: 43-47.;;Cassels, et al., Analysis of Escherichia coli Colonization Factor Antigen I Linear B-Cell Epitopes, as Determined by Primate Responses, following Protein Sequence Verification, Infection and Immunity, Jun. 1992, p. 2174-2181, vol. 60, No. 6.;;Romagnoli, et al. Peptide-MHC Interaction: A Rational Approach to Vaccine Design, Inter, RE. Immunol. 6, 1990, 00 61-73.;;Maister, First Oral AIDS Vaccine Trials Near, BioWorld Today, Tuesday, Apr. 19, 1994, p. 4.;;Rognan, et al., Molecular Modeling of an Antigenic Complex Between a Viral Peptide and a Class I Major Histocompatibility Glycoprotein, Proteins Structure, Function and Genetics 13 70-85 (1992).;;Brown, A hypothetical model of the foreign antigen biinding site of Class II histocompatibility molecules, Nature, vol. 332, Apr. 28, 1988, p845-850.",EXPIRED
